Renee-Claude Mercier
Overview
Explore the profile of Renee-Claude Mercier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asselah T, Lampertico P, Aleman S, Bourliere M, Streinu-Cercel A, Bogomolov P, et al.
Liver Int
. 2024 Dec;
45(4):e16174.
PMID: 39648559
Background And Aims: The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients...
2.
Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pantea V, et al.
N Engl J Med
. 2024 Jun;
391(2):133-143.
PMID: 38842520
Background: In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label...
3.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al.
J Hepatol
. 2024 May;
81(4):621-629.
PMID: 38734383
Background & Aims: Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed treatment at week...
4.
Flamm S, Lawitz E, Borg B, Charlton M, Landis C, Reddy K, et al.
Viruses
. 2023 Oct;
15(10).
PMID: 37896803
A fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) plus weight-based ribavirin (RBV) for 12 weeks is recommended for the treatment of patients with hepatitis C virus (HCV)-associated decompensated cirrhosis. However, large global...
5.
Thelen H, Dilworth T, Mercier R
Chemotherapy
. 2022 Nov;
67(4):261-268.
PMID: 36417841
Introduction: Community-acquired urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli have limited oral therapeutic options and pose significant clinical challenges. The goal of this study was to...
6.
Hernandez B, Dilworth T, Kesner J, Ryan K, Thelen H, Mercier R
Chemotherapy
. 2022 Aug;
68(1):55-60.
PMID: 36001946
Introduction: Recent evidence has shown that oral antibiotic therapy is not inferior to IV antibiotic therapy in the treatment of complicated Staphylococcus aureus infections. Therefore, oral antibiotic therapy is now...
7.
Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan
Takehara T, Izumi N, Mochida S, Genda T, Fujiyama S, Notsumata K, et al.
Hepatol Res
. 2022 Jul;
52(10):833-840.
PMID: 35802063
Background & Purpose: Protease-free regimens for chronic hepatitis C virus (HCV) infection are safe and effective for persons with either compensated or decompensated cirrhosis. We examined the efficacy and safety...
8.
Anderson B, Mercier R
J Am Pharm Assoc (2003)
. 2022 Mar;
62(4):1158-1161.
PMID: 35314118
In 2019, the executive branch of the United States released "Ending the Human Immunodeficiency Virus (HIV) Epidemic: A Plan for America" (EHE). EHE proposes to end the HIV epidemic in...
9.
Custodio M, Sanchez D, Anderson B, Ryan K, Walraven C, Mercier R
Antimicrob Agents Chemother
. 2020 Nov;
65(2).
PMID: 33139285
We examined the effects of piperacillin-tazobactam (TZP) concentration and bacterial inoculum on killing and the emergence of resistance in The MICs for 15 clinical respiratory isolates were determined by broth...
10.
Dilworth T, Sanchez D, Anderson B, DeAngelis H, Mercier R
Chemotherapy
. 2020 May;
64(5-6):233-237.
PMID: 32396913
Previous studies have demonstrated synergy between piperacillin (PIP)-tazobactam (TAZ) (TZP) and vancomycin (VAN) against methicillin-resistant Staphylococcus aureus (MRSA). However, it is unknown whether PIP and/or TAZ synergizes with VAN against...